Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa neoadjuvant local and intratumoral PTS injection in early-stage head and neck squamous cell carcinoma
ChiCTR-ONC-12002948Phase 2Completed
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- May 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of para-toluenesulfonamide in head and neck squamous cell carcinoma (HNSCC) and squamous cell carcinoma (SCC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Histologic and pathologic changes in tumor tissue and adjacent normal tissue and Efficacy evaluation by RECIST and WHO criteria. Started May 2002; status: completed.
02
Drugs
para-toluenesulfonamide
03
Conditions
head and neck squamous cell carcinoma (HNSCC)squamous cell carcinoma (SCC)
Beyond the preview
Go deeper on ChiCTR-ONC-12002948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONC-12002948.